作者
Ruth B Caldwell, Manuela Bartoli, M Ali Behzadian, Azza EB El-Remessy, Mohamed Al-Shabrawey, Daniel H Platt, Gregory I Liou, R William Caldwell
发表日期
2005/6/1
来源
Current drug targets
卷号
6
期号
4
页码范围
511-524
出版商
Bentham Science Publishers
简介
Retinal neovascularization and macular edema are central features of diabetic retinopathy, a major cause of blindness in working age adults. The currently established treatment for diabetic retinopathy targets the vascular pathology by laser photocoagulation. This approach is associated with significant adverse effects due the destruction of neural tissue and is not always effective. Characterization of the molecular and cellular processes involved in vascular growth and hyperpermeability has led to the recognition that the angiogenic growth factor and vascular permeability factor VEGF (vascular endothelial growth factor) play a pivotal role in the retinal microvascular complications of diabetes. Thus, VEGF represents an important target for therapeutic intervention in diabetic retinopathy. Agents that directly inhibit the actions of VEGF and its receptors show considerable promise, but have not proven to be completely …
引用总数
20052006200720082009201020112012201320142015201620172018201920202021202220232024110243424242519271323171478811743
学术搜索中的文章